Skip to main content
Equibles
PRTA logo

PRTA · Prothena Corp Public Ltd Co · Investor Relations

Track PRTA — free

Use PRTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.36 -0.18 (-2.11%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$425.58M
Shares
51.34M
Volume · Oct 2 675.84K Avg daily vol (3M) 473.57K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-09 Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-06 Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
2026-07-30 Prothena to Report Second Quarter 2026 Financial Results on August 6
2026-05-07 Prothena Reports First Quarter 2026 Financial Results and Business Highlights
2026-04-30 Prothena to Report First Quarter 2026 Financial Results on May 7
2026-04-27 Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
2026-04-10 Prothena Announces Leadership Team Updates
2026-03-21 Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
2026-03-09 Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
2026-02-27 Prothena Announces up to $100 Million Share Repurchase Plan
2026-02-19 Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
2026-02-12 Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
2025-12-12 Prothena Announces Board of Directors Update

Past events

Date Event Type
2026-09-16 H.C. Wainwright Global Investment Conference Conference
2026-09-16 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-03-21 ADPD 2026: Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease Presentation
2026-03-11 Citizens Life Sciences Conference Conference
2026-02-19 Prothena Fourth Quarter and Full Year 2025 Financial Results Conference Call Earnings call
2025-12-04 Evercore Healthcare Conference Conference
2025-12-03 Piper Sandler Annual Healthcare Conference Conference
2025-11-10 AHA25: Late-Breaking Presentation of Primary Results from the Phase 2 Coramitug Clinical Trial in ATTR-CM Presentation
2025-09-04 Cantor Global Healthcare Conference Conference
2025-04-01 ADPD 2025: PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment Event
2025-02-20 Prothena Fourth Quarter and Full Year 2024 Financial Results Conference Call Earnings call
2024-09-17 Cantor Global Healthcare Conference Conference
2024-03-12 Leerink Partners Global Biopharma Conference Conference
2024-02-15 Prothena Fourth Quarter and Full Year 2023 Financial Results Conference Call Earnings call
2023-09-11 Morgan Stanley Healthcare Conference Conference
2023-07-17 AAIC 2023 Poster Presentation: PRX005, A Novel Anti-MTBR Tau Humanized Monoclonal Antibody: Results from the Single Ascending Dose Portion of a First-in-Human Double-Blind, Placebo-Controlled, Phase 1 Clinical Trial Presentation
2023-07-17 AAIC 2023 Poster Presentation: Immunological response to dual Aβ/Tau vaccine PRX123 surrogate and effects on brain amyloid plaques in rapidly depositing transgenic animal model Presentation
2023-07-17 AAIC 2023 Poster Presentation: Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Aβ Protofibrils and Robust Clearance of Pyroglutamate-Modified Aβ Presentation
2023-06-08 Jefferies Healthcare Conference Conference
2023-05-09 Bank of America Healthcare Conference Conference
2023-03-31 ADPD 2023 Oral Presentation: Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Abeta Protofibrils and Robust Clearance of Pyroglutamate-Modified Abeta Presentation
2023-02-23 Prothena Fourth Quarter and Full Year 2022 Financial Results Conference Call Earnings call
2022-02-17 Prothena Fourth Quarter and Full Year 2021 Financial Results Conference Call Earnings call

Source: https://ir.prothena.com/overview/default.aspx

Key facts CIK 1559053 CUSIP G72800108 13F (30d) 5 filings 5 filers Visit website Investor relations